These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16969674)

  • 61. Sublingual immunotherapy.
    Heinzerling L; Worm M; Bergmann KC; Zuberbier T
    J Dtsch Dermatol Ges; 2006 May; 4(5):428-33; quiz 434-5. PubMed ID: 16686612
    [No Abstract]   [Full Text] [Related]  

  • 62. Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis.
    Senna GE; Andri G; Dama AR; Falagiani P; Andri L
    Allergol Immunopathol (Madr); 2000; 28(4):238-42. PubMed ID: 11022271
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
    Rossi RE; Monasterolo G
    Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of immunotherapy delivery methods for allergen immunotherapy.
    Klimek L; Pfaar O
    Expert Rev Clin Immunol; 2013 May; 9(5):465-74; quiz 475. PubMed ID: 23634740
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recent progress in allergen immunotherapy.
    Nouri-Aria KT
    Iran J Immunol; 2008 Mar; 5(1):1-24. PubMed ID: 18319521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.
    Rose K; Kopp MV
    Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: A systematic review and meta-analysis.
    Jiang Z; Xiao H; Zhang H; Liu S; Meng J
    Am J Otolaryngol; 2019; 40(6):102269. PubMed ID: 31422860
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gaps in allergen immunotherapy administration and subcutaneous allergen immunotherapy dose adjustment schedules: Need for prospective data.
    Larenas-Linnemann DE; Epstein T; Ponda P; Bernstein D; Williams P; Creticos P
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):505-506.e2. PubMed ID: 32693206
    [No Abstract]   [Full Text] [Related]  

  • 71. Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis.
    Pfaar O; Angier E; Muraro A; Halken S; Roberts G
    Allergy; 2020 Sep; 75(9):2411-2414. PubMed ID: 32163594
    [No Abstract]   [Full Text] [Related]  

  • 72. Recent developments and highlights in rhinitis and allergen immunotherapy.
    Reitsma S; Subramaniam S; Fokkens WWJ; Wang Y
    Allergy; 2018 Dec; 73(12):2306-2313. PubMed ID: 30260494
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.
    Barth C; Anero F; Pfaar O; Klimek L; Hörmann K; Stuck BA
    Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1873-9. PubMed ID: 20454971
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Beta glucuronidase short-term immunotherapy.
    Di Stanislao C; Angelini F; Gagliardi MC; Di Bernardino L; Fundaro' C; Galli E; Rossi P
    Allergy; 2003 May; 58(5):459. PubMed ID: 12752344
    [No Abstract]   [Full Text] [Related]  

  • 75. [Practice patterns in Mexican allergologists about specific immunotherapy with allergens].
    Larenas Linnemann D; Guidos Fogelbach GA; Arias Cruz A
    Rev Alerg Mex; 2008; 55(2):53-61. PubMed ID: 19058482
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Mechanisms of specific immunotherapy].
    Bellinghausen I; Knop J; Saloga J
    Hautarzt; 2006 Oct; 57(10):855-9. PubMed ID: 16955304
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Application of immunotherapy in Catalonia (Spain)].
    Paniagua MJ; Botey E; López-Abad R; Gázquez V; Richart C; Gaig P
    Allergol Immunopathol (Madr); 2004; 32(5):284-8. PubMed ID: 15456625
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Compounding a Problem?
    Berlin J
    Tex Med; 2016 May; 112(5):63-9. PubMed ID: 27175928
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Immunologic control parameters during specific immunotherapy].
    Ott H; Wosnitza M; Merk HF
    Hautarzt; 2008 Jul; 59(7):551-6. PubMed ID: 18553185
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Internists--Update 2006].
    Stiefelhagen P
    Internist (Berl); 2007 Feb; 48(2):213-6. PubMed ID: 17216506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.